Literature DB >> 11489759

Regular use of analgesic drugs and ovarian cancer risk.

K B Moysich1, C Mettlin, M S Piver, N Natarajan, R J Menezes, H Swede.   

Abstract

Analgesics have been shown to reduce risk for colorectal cancer. Results from three recent reports (D. W. Cramer et al., Lancet, 351: 104-107, 1998; C. Rodriguez et. al., Lancet, 352: 1354-1355, 1998; L. Rosenberg et al., Cancer Epidemiol. Biomark. Prev., 9: 933-937, 2000) suggest that these drugs might be associated with decreased risk for ovarian cancer. In this hospital-based case-control study, we compared 547 patients with ovarian cancer to 1094 age-matched patients with nonneoplastic conditions. All of the participants received treatment at the Roswell Park Cancer Institute between 1982 and 1998 and completed a comprehensive epidemiological questionnaire that included information on demographics, life-style factors, and reproductive characteristics as well as frequency and duration of aspirin and acetaminophen use. Women who reported that they had used one or more of these agents at least once a week for at least 6 months were classified as analgesic users. Logistic regression was used to compute crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Aspirin users were not at reduced risk of ovarian cancer compared with nonusers (adjusted OR, 1.00; CI, 0.73-1.39). There was also no evidence of a decrease in risk as a function of greater frequency of use or prolonged duration of use. Regular acetaminophen use was associated with a reduced risk (adjusted OR, 0.56; 95% CI, 0.34-0.86), and risk reductions were observed for women with the greatest frequency of use (adjusted OR, 0.32; 95% CI, 0.09-1.08) and longest duration of use (adjusted OR, 0.51; 95% CI, 0.27-0.97). These data suggest that regular use of acetaminophen, but not aspirin, may be associated with lower risk of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489759

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  29 in total

1.  Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort.

Authors:  Veronica Wendy Setiawan; Rayna K Matsuno; Galina Lurie; Lynne R Wilkens; Michael E Carney; Brian E Henderson; Laurence N Kolonel; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-04       Impact factor: 4.254

2.  Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.

Authors:  Xiaojian Ni; Jingjing Ma; Yingchun Zhao; Ying Wang; Shui Wang
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  The effect of secondhand smoke exposure on the association between active cigarette smoking and colorectal cancer.

Authors:  Luke J Peppone; Mary E Reid; Kirsten B Moysich; Gary R Morrow; Pascal Jean-Pierre; Supriya G Mohile; Tom V Darling; Andrew Hyland
Journal:  Cancer Causes Control       Date:  2010-04-08       Impact factor: 2.506

4.  Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.

Authors:  Nonna V Kolomeyevskaya; J Brian Szender; Gary Zirpoli; Albina Minlikeeva; Grace Friel; Rikki A Cannioto; Rachel M Brightwell; Kassondra S Grzankowski; Kirsten B Moysich
Journal:  Int J Gynecol Cancer       Date:  2015-11       Impact factor: 3.437

5.  Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Nikolaos M Sitaras
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

6.  Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk.

Authors:  Simone P Pinheiro; Margaret A Gates; Immaculata De Vivo; Bernard A Rosner; Shelley S Tworoger; Linda Titus-Ernstoff; Susan E Hankinson; Daniel W Cramer
Journal:  Int J Mol Epidemiol Genet       Date:  2010-09-03

7.  Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice.

Authors:  Wei Li; Zhong-lei Ji; Guang-chao Zhuo; Ru-jun Xu; Jie Wang; Hong-ru Jiang
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

8.  Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.

Authors:  Bing Xin; Yoshihito Yokoyama; Tatsuhiko Shigeto; Hideki Mizunuma
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

9.  Cyclooxygenase-1 inhibition prolongs postnatal ovarian follicle lifespan in mice.

Authors:  Elizabeth R Smith; Wan-Lin Yang; Toni Yeasky; Jennifer Smedberg; Kathy Q Cai; Xiang-Xi Xu
Journal:  Biol Reprod       Date:  2013-10-31       Impact factor: 4.285

10.  Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Authors:  Stephen H Bush; Sharon Tollin; Douglas C Marchion; Yin Xiong; Forough Abbasi; Ingrid J Ramirez; Nadim Bou Zgheib; Bernadette Boac; Patricia L Judson; Hye Sook Chon; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Anders E Berglund; Laura J Havrilesky; Johnathan M Lancaster
Journal:  Mol Clin Oncol       Date:  2016-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.